全文获取类型
收费全文 | 71297篇 |
免费 | 8324篇 |
国内免费 | 2587篇 |
专业分类
耳鼻咽喉 | 445篇 |
儿科学 | 1238篇 |
妇产科学 | 568篇 |
基础医学 | 6326篇 |
口腔科学 | 473篇 |
临床医学 | 6147篇 |
内科学 | 9279篇 |
皮肤病学 | 362篇 |
神经病学 | 407篇 |
特种医学 | 3121篇 |
外国民族医学 | 124篇 |
外科学 | 7737篇 |
综合类 | 13079篇 |
现状与发展 | 18篇 |
预防医学 | 2344篇 |
眼科学 | 194篇 |
药学 | 5322篇 |
41篇 | |
中国医学 | 2755篇 |
肿瘤学 | 22228篇 |
出版年
2024年 | 242篇 |
2023年 | 1318篇 |
2022年 | 2635篇 |
2021年 | 3592篇 |
2020年 | 3145篇 |
2019年 | 2583篇 |
2018年 | 2441篇 |
2017年 | 2955篇 |
2016年 | 3274篇 |
2015年 | 3658篇 |
2014年 | 4928篇 |
2013年 | 4687篇 |
2012年 | 4428篇 |
2011年 | 4697篇 |
2010年 | 3821篇 |
2009年 | 3533篇 |
2008年 | 3568篇 |
2007年 | 3789篇 |
2006年 | 3393篇 |
2005年 | 3070篇 |
2004年 | 2465篇 |
2003年 | 2077篇 |
2002年 | 1722篇 |
2001年 | 1508篇 |
2000年 | 1285篇 |
1999年 | 1016篇 |
1998年 | 933篇 |
1997年 | 834篇 |
1996年 | 677篇 |
1995年 | 523篇 |
1994年 | 498篇 |
1993年 | 374篇 |
1992年 | 388篇 |
1991年 | 310篇 |
1990年 | 275篇 |
1989年 | 228篇 |
1988年 | 223篇 |
1987年 | 191篇 |
1986年 | 157篇 |
1985年 | 136篇 |
1984年 | 119篇 |
1983年 | 90篇 |
1982年 | 86篇 |
1981年 | 79篇 |
1980年 | 80篇 |
1979年 | 57篇 |
1978年 | 34篇 |
1977年 | 28篇 |
1976年 | 14篇 |
1975年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
23.
目的 探究原发灶定位与甲状腺乳头状微小癌(PTMC)颈侧区淋巴结转移的关系,评估超声检查预测颈侧区淋巴结转移的准确率。方法 回顾性分析2014年1月至2015年12月天津医科大学肿瘤医院收治的134例PTMC病人的临床资料,均行中央区淋巴结清扫+改良颈侧区淋巴结清扫。依据超声定位分组,分析癌灶位置与颈侧区淋巴结转移的关系。结果 颈侧各分区淋巴结转移发生率分别为:Ⅱ区30.6%、Ⅲ区50.7%、Ⅳ区57.5%、Ⅴ区11.3%。癌灶位于中上极者颈侧区淋巴结转移发生率高于癌灶位于下极者(89.7% vs. 75.7%,P=0.038),靠近外侧者较内侧者更易出现颈侧区淋巴结转移(93.7% vs. 81.4%,P=0.049)。超声检查判定Ⅱ、Ⅲ、Ⅳ、Ⅴ区淋巴结转移的敏感度分别为43.9%、85.3%、85.7%、14.3%;特异度为91.4%、57.6%、35.1%、99.1%。超声预测Ⅲ、Ⅳ区淋巴结转移敏感度较高,Ⅱ、Ⅴ区淋巴结转移特异度较高。结论 癌灶位置与甲状腺微小癌颈侧区淋巴结转移密切相关,超声可为临床确定颈侧区淋巴结的清扫范围提供依据。 相似文献
24.
The term “oligometastatic prostate cancer” refers to a heterogeneous group of disease states currently defined solely on the basis of clinical features. Oligorecurrent disease, de novo oligometastases, and oligoprogressive disease likely have unique biologic underpinnings and natural histories. Evidence suggesting the existence of a subset of patients who harbor prostate cancer with limited metastatic potential currently includes disparate and overwhelmingly retrospective reports. Nevertheless, emerging prospective data have corroborated the “better-than-expected,” retrospectively observed outcomes, particularly in the setting of oligorecurrent prostate cancer. Improved functional imaging with prostate-specific membrane antigen-targeted strategies may enhance the identification of patients with oligometastatic prostate cancer in the short term. In the long term, refinement of the oligometastatic case definition likely will require biologic risk-stratification schemes. To determine optimal treatment strategies and identify patients most likely to benefit from metastasis-directed therapy, future efforts should focus on conducting high-quality, prospective trials with much-needed molecular correlative studies. 相似文献
25.
26.
目的:研究乳腺癌细胞中转录调节因子c-Myb的表达对肺转移的影响及其分子机制。方法:构建c-Myb高表达的4T1乳腺癌细胞株,种植小鼠构建乳腺癌动物模型,检测实验动物肺转移情况,通过荷瘤抑制试验检测肺转移抑制效果。提取组织进行荧光PCR检测相关炎症因子的表达。利用Medisapiens数据库的生物信息学资源,对c-Myb和Ccl2的表达与乳腺癌患者的预后进行分析。结果:高表达c-Myb的荷瘤小鼠肺部转移灶明显减少,其中炎症相关因子表达受限。由数据库分析得出,c-Myb高表达患者生存期得以延长。结论:乳腺癌中c-Myb的表达能够通过炎症因子Ccl2抑制肺转移从而延长患者生存期。 相似文献
27.
28.
AimsIn response to the COVID-19 pandemic, guidelines on reduced fractionation for patients treated with curative-intent radiotherapy were published, aimed at reducing the number of hospital attendances and potential exposure of vulnerable patients to minimise the risk of COVID-19 infection. We describe the changes that took place in the management of patients with stage I–III lung cancer from April to October 2020.Materials and methodsLung Radiotherapy during the COVID-19 Pandemic (COVID-RT Lung) is a prospective multicentre UK cohort study. The inclusion criteria were: patients with stage I–III lung cancer referred for and/or treated with radical radiotherapy between 2nd April and 2nd October 2020. Patients who had had a change in their management and those who continued with standard management were included. Data on demographics, COVID-19 diagnosis, diagnostic work-up, radiotherapy and systemic treatment were collected and reported as counts and percentages. Patient characteristics associated with a change in treatment were analysed using multivariable binary logistic regression.ResultsIn total, 1553 patients were included (median age 72 years, 49% female); 93 (12%) had a change to their diagnostic investigation and 528 (34%) had a change to their treatment from their centre's standard of care as a result of the COVID-19 pandemic. Age ≥70 years, male gender and stage III disease were associated with a change in treatment on multivariable analysis. Patients who had their treatment changed had a median of 15 fractions of radiotherapy compared with a median of 20 fractions in those who did not have their treatment changed. Low rates of COVID-19 infection were seen during or after radiotherapy, with only 21 patients (1.4%) developing the disease.ConclusionsThe COVID-19 pandemic resulted in changes to patient treatment in line with national recommendations. The main change was an increase in hypofractionation. Further work is ongoing to analyse the impact of these changes on patient outcomes. 相似文献
29.
肺癌是目前全球发病率和死亡率均居前列的恶性肿瘤,其中肺鳞癌经手术、放化疗等综合治疗后,其疗效仍不满意。随着分子靶向治疗在肺腺癌中取得了令人瞩目的成果,而肺鳞癌患者中EGFR基因突变及ALK融合基因少见,急需探索新的靶点指导肺鳞癌患者的临床治疗。研究表明,FGFR家族(FGFR1-4)是肺鳞癌中突变频率较高的基因,FGFR基因的激活突变和扩增与肺鳞癌的发生和发展密切相关,同时许多小分子 FGFR 抑制剂在临床应用中已经取得较好的治疗效果。目前,许多FGFR抑制剂治疗肺鳞癌的临床试验也正在进行研究,针对FGFR靶点的基因治疗可为肺鳞癌的治疗提供一种新的策略。本文就FGFR在肺鳞癌的靶向治疗中的最新研究进展进行综述。 相似文献
30.
Chien-Hua Tseng Ben-Jei Tsuang Chun-Ju Chiang Kai-Chen Ku Jeng-Sen Tseng Tsung-Ying Yang Kuo-Hsuan Hsu Kun-Chieh Chen Sung-Liang Yu Wen-Chung Lee Tsang-Wu Liu Chang-Chuan Chan Gee-Chen Chang 《Journal of thoracic oncology》2019,14(5):784-792